Sex and gender differences have been reported in atrial fibrillation (AF), especially in
relation to differences in thromboembolic and bleeding risks. More recently …

Aims Oral anticoagulants (OACs) are crucial for treating atrial fibrillation (AF) patients at high
thromboembolic risk. However, in AF patients at intermediate thromboembolic risk with a …

Sex‐specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …

Introduction Limited information exists on gender-related differences in the safety and
efficacy of non-vitamin K antagonist oral anticoagulants (NOACs). Aim of the Study To …

Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an increased
thromboembolic risk. The impact of the female sex as an independent risk factor for …

Non-vitamin K oral anticoagulants (NOACs) are increasingly used as alternatives to
conventional therapies and have considerable accumulated real-world clinical data in …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …